Access our complete catalogue of cancer immunotherapy clinical practice guidelines using the SITC CPG Mobile App.
Novel Coronavirus (COVID-19) Statement
Missed a live ACI topic from the last series? You can now watch the recordings for credit, as well as access interactive courses to supplement your knowledge! The online courses listed below are CME-, CPE-, CNE- and MOC-certified supplemental program courses for the ACI education series. Participation by clinicians is strongly recommended, however the courses are available to anyone.
Introduction to ImmunotherapyThis interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy. Basic Principles of Cancer ImmunotherapyThis course, Basic Principles will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.
Missed a recent live ACI, or looking for an interactive dive into the topics presented? SITC recommends the below courses to earn your CE's and continue to learn on at your own pace.
ACI Online Programs
ACI Enduring Materials
ACI Registration Info
Technology Information and Policy
The 2021-2022 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Association of Community Cancer Centers, Advanced Practitioner Society for Hematology and Oncology, and the Hematology/Oncology Pharmacy Association.
The ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc. (as of 10/13/2021)
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org